Pustulosis palmaris et plantaris or palmoplantar pustulosis (PPP) is a refractory pustular eruption on the palms and soles with unknown etiology. Numerous eccrine sweat pores exist on the palms and soles, suggesting the involvement of eccrine sweating in the pathogenesis of PPP. To the best of our knowledge, however, no definite abnormality in sweating has been documented in PPP. Accordingly, we analyzed the eccrine sweat duct involvement in the mechanism of vesicle formation in PPP. Dermatoscopy showed that PPP vesicles are located on the top of the ridges but not in the furrows. The sweat secretion in the lesional area was much lower than that in the nonlesional area, with or without pain stimulation to induce sweating. Immunostaining of horizontal sections of the lesions using antibodies against gross cystic disease fluid protein-15 (GCDFP-15) and epithelial membrane antigen (EMA) showed that these markers were localized in the cells lining the intraepidermal vesicles. Although the sweat antimicrobial peptides, dermcidin and human cathelicidin antimicrobial peptide 18 (hCAP-18)/LL-37, were detected in the fluid of the vesicles/pustules, neither dermcidin nor hCAP-18/LL-37 were overexpressed by neighboring keratinocytes. These findings suggest that the acrosyringium may be involved as the main site of the vesicle formation in the pathomechanism of PPP.
INTRODUCTION
Pustulosis palmaris et plantaris or palmoplantar pustulosis (PPP) is a chronic pustular dermatitis characterized by palmoplantar intraepidermal vesicles filled with neutrophils (Uehara and Ofuji, 1974) . Although it is a common skin disease often recalcitrant to available treatments, the pathogenesis remains unknown. Numerous eccrine sweat pores exist on the palms and soles, and several reports suggest the involvement of eccrine sweating in the pathogenesis of PPP (Krieg et al., 1992; Eriksson et al., 1998) . To the best of our knowledge, however, no definite abnormality in sweating has been documented in PPP.
The eccrine sweat gland is a secretory as well as an excretory organ. Although the sole function of sweat has been considered to be thermoregulation during exposure to a hot environment or during physical exercise, recent evidence indicates that it has a role in the innate immune response. Previously, two major classes of antimicrobial peptides were identified in mammalian skin: cathelicidins (Zanetti et al., 1995; Gallo et al., 1997; Nizet et al., 2001) and b-defensins (Harder et al., 1997; Stolzenberg et al., 1997; Ali et al., 2001) . Cathelicidins, which are similar to many other antimicrobial peptides, are synthesized as a preproprotein (Zanetti et al., 1995) . The only cathelicidin in humans is human cathelicidin antimicrobial peptide (hCAP-18)/LL-37 (Agerberth et al., 1995; Frohm et al., 1997) and it is expressed in leukocytes as well as on a variety of epithelial surfaces. The hCAP-18/LL-37 has been detected in human skin keratinocytes, but only at the site of inflammation, suggesting that this antimicrobial peptide functions primarily in response to injury rather than modulating colonization of the skin's surface (Frohm et al., 1997) . Another antimicrobial peptide, dermcidin, was recently detected in the human sweat gland, suggesting that sweat may have an additional important role in protection against various bacteria (Schittek et al., 2001) . Recently, we have shown the expression of hCAP-18/LL-37 in eccrine sweat glands , which confirms the role of antimicrobial peptides in protecting the body surface through innate immunity.
To dissect the involvement of the eccrine sweat duct in the pathomechanism of vesicle formation in PPP, a possible abnormality in the process of sweating was analyzed in early lesions of PPP. Because the vesicle formation can be rapidly induced by infection, stress, and so on, it is plausible to speculate that the preexisting acrosyringium is involved in the formation of the lesion. Our data provide a support for the hypothesis that an abnormality in sweating initiates the formation of vesicles, suggesting a pathophysiological mechanism for PPP.
RESULTS

PPP vesicles were located on the ridges of palmar skin
Dermatoscopy clearly showed that small vesicles and vesicopustules were located in a linear manner on the top of the ridges but not in the furrows of the palmar skin ( Figure 1 ). Some large vesicles or pustules extended into the furrows.
Sweat secretion in the lesional area was decreased compared with that in the nonlesional area Sweat secretion was compared between the lesional and nonlesional areas of the palmar skin. At the time of measurement, the patient's palm showed several small vesicles with a few pustules. Sweat volume in the lesional area (B) was much lower than that in the non-lesional area (A) or the contralateral healthy palm(s) ( Figure 2 ). The sweat volume in the nonlesional area was increased after pain stimulation, whereas that in the lesional area remained low.
Small vesicles were located in/and around the epidermal sweat ducts in the early lesions PPP vesicles were located within the epidermis, with typical pustule formation ( Figure 3 ). Keratinous material in the acrosyringium was also observed (Figure 3a) . A small vesicle related to acrosyringium could be observed in the epidermis (Figure 3b ). The vesicle turned into a tiny pustule filled with small round cells and neutrophils (Figure 3c ). Microabscess formation was observed in the epidermis with remarkable inflammatory cell infiltration around the pustule (Figure 3d ). Finally, the lesion resolved to normal-appearing epidermis (Figure 3e ). Using horizontal sections, immunostaining with gross cystic disease fluid protein 15 (GCDFP-15) and epithelial membrane antigen (EMA) showed that these signals were localized to the acrosyringium showing pores in the epidermis and the lining cells of the intraepidermal vesicles ( Figure 4 ).
Expression of dermcidin and hCAP-18/LL-37 was not increased in the keratinocytes around the vesicle formation Dermcidin and hCAP-18/LL-37 were detected in the sweat duct in the stratum corneum in addition to the dermal eccrine sweat ducts ( Figure 5 ). However, neither dermcidin nor hCAP-18/LL-37 was overexpressed in the keratinocytes around the vesicles ( Figure 5 ). The hCAP-18/LL-37 was abundantly expressed in the polymorphonuclear neutrophils (PMNs) in the pustules but dermcidin was not detected (data not shown).
The expression of dermcidin and hCAP-18/LL-37 in PPP vesicles/pustules
The sweat antimicrobial peptides, dermcidin and hCAP-18/ LL-37, were detected in the PPP vesicles/pustules ( Figure 6 ). Dot blots performed for the detection of dermcidin showed positive signals in the PPP vesicles/pustules. The hCAP-18/LL-37 western blots showed three bands (18 kd, full length; 15 kd, intermediate sized; and 4.5 kD; mature form), as was already reported previously in sweat . All five samples of vesicles/pustules showed the same result, and the representative data are shown in the figure.
The hCAP-18/LL-37 mRNA was not upregulated in lesional PMNs
PMNs are known to contain hCAP-18/LL-37. To dissect the origin of hCAP-18/LL-37 proteins, LL-37 mRNA expression in the lesional and blood PMNs (L-and B-PMNs) were analyzed with both reverse transcription-PCR and real-time PCR (Figure 6c ). Both L-and B-PMNs contained hCAP-18/LL-37 mRNA. However, there was no significant difference in the mRNA expression levels between L-and B-PMNs as assessed by real-time PCR (Figure 6d ). All five samples of PMNs showed the same result, and the representative data are shown in the figure.
DISCUSSION
The etiology of PPP remains unknown, and whether PPP and localized pustular psoriasis are distinct entities is still controversial (Christpher and Mrowietz, 2003; Griffiths et al., 2004) . However, typical PPP usually presents in patients who do not have a personal or family history of psoriasis. Furthermore, the absence of immunogenetic associations of PPP with psoriasis suggests that PPP may represent a separate and distinct entity (Christpher and Mrowietz, 2003; Griffiths et al., 2004) . Our dermatoscopic findings as well as our documentation of reduced local sweat volume in the lesional area(s) are consistent with the notion that the acrosyringium specifically is involved in the pathogenesis of PPP (Eriksson et al., 1998) . GCDFP-15, a conventional marker for the apocrine gland, also cross-reacts with the eccrine glands (Viacava et al., 1998) . Our results document that the lining cells of the vesicles are positive for GCDFP-15 in addition to EMA, suggesting that the main component of the vesicles could be enlarged or destroyed acrosyringium. Several histopathological studies regarding the origin of PPP have been published (Uehara and Ofuji, 1974) . In brief, the first phase of this disease is characterized by spongiosis or epidermal vesicle formation followed by the purulent eruption during the second phase. The pustulation begins when direct contact between the blister fluid and the stratum corneum occurs (Uehara and Ofuji, 1974) .
Investigations on the mechanism of the formation of subcorneal sterile pustules have focused on the chemotactic factors for PMNs (Bruch-Gerharz et al., 1996; Gillitzer et al., 1996; Kulke et al., 1996; Ozawa et al., 2005) , which include IL-8 and components of complement (Anttila et al., 1992; Ozawa et al., 2005) . Immunohistochemical studies showed that intracellular epidermal IL-8 was consistently detected in both PPP and psoriasis but not in nonlesional or healthy control skin. HuMab 10F8, which to our knowledge is a previously unreported human mAb against IL-8, significantly reduced clinical disease activity of PPP by inhibiting the formation of fresh pustules (Skov et al., 2008) . C3b was also detected on the subcorneal keratinocyte cell membranes (Ozawa et al., 2005) , suggesting that complement is also responsible for the intraepidermal migration of PMNs (Ozawa et al., 2005) .
Recent evidence indicates that skin antimicrobial peptides are also chemotactic for PMNs (De et al., 2000) . The peptides, such as cathelicidin (Frohm et al., 1997; Gallo et al., 1997; Bals et al., 1998) , defensins (Ali et al., 2001) , and dermcidin (Schittek et al., 2001) , are essential elements of the epithelial defense system that participate in a variety of immune mechanisms in both a direct and indirect manner (Gallo et al., 2002; Zasloff, 2002) . For human sweat glands, the constitutive expression of dermcidin and inducible expression of cathelicidin have been documented (Schittek et al., 2001; Murakami et al., 2002) . Using these peptides as a marker for sweat, we obtained the evidence that the PPP patients had an abnormal sweat secretion.
Dot-blot and western blot analyses showed that the vesicle and pustule fluid contains the same antimicrobial peptides that are found in sweat. It has been reported that dermcidin is continuously secreted in the eccrine sweat but is not induced during inflammation (Schittek et al., 2001; Rieg et al., 2004) , whereas cathelicidins are induced under inflammatory conditions such as psoriasis and wound healing (Frohm et al., 1997; Gallo et al., 2002) . It is known that the source of cathelicidin is the granules of the PMNs (Sorensen et al., Figure 6 . Palmoplantar pustulosis (PPP) vesicles/pustules contain both dermcidin and hCAP-18/LL-37; however, no upregulation of LL-37 mRNA in lesional PMNs of PPP was seen. (a) A western blot for human cathelicidin antimicrobial peptide 18 (hCAP-18)/LL-37 shows three bands (18, 15, and 4.5 Kd), suggesting the sweat hCAP-18/LL-37 expression pattern as previously described. Polymorphonuclear leukocytes of the peripheral blood (PMN) and LL-37 synthetic peptide (LL-37) were applied as positive controls, and dermcidin as a negative control, respectively (these lanes were not originally run next to each other). (b) The dot blot showed that vesicles from PPP contain dermcidin. Dermcidin synthetic peptide (derm) was applied as a positive control, and dermcidin precursor protein Y-P 30 (Y-P 30) and PMN were applied as negative controls. LL-37 mRNA expression in the lesional and 1997, 2001) . Therefore, we analyzed whether the cathelicidin also comes from the surrounding keratinocytes of the lesion. Both dermcidin and hCAP-18/LL-37 were documented in the sweat duct in the stratum corneum in addition to the eccrine sweat ducts in the dermis, as reported previously (Schittek et al., 2001; Murakami et al., 2002) . However, no dermcidin or hCAP-18/LL-37 overexpressions were detected in keratinocytes around the vesicles. This suggests that neither dermcidin nor hCAP-18/LL-37 in the fluid came from the surrounding keratinocytes. Quantitative real-time PCR also disclosed no significant difference in the mRNA expression levels between L-and B-PMNs. On the basis of these findings, we conclude that cathelicidin in the vesicle fluid originated mainly from the sweat-derived contents of the acrosyringium. Eriksson et al. (1998) recently performed a clinical and immunohistological study of PPP, and proposed that the acrosyringium was possibly involved in this disease. This hypothesis was based on the observation that the epidermal eccrine duct structure was not present in any of the specimens from PPP, whereas it was present in all of the control specimens (Eriksson et al., 1998) . In contrast, our results clearly show the involvement of the acrosyringium in the PPP vesicle formation, suggesting that the disease originates from the acrosyringium. However, it is still unclear why the acrosyringium is involved at the initiation of this process, and whether external pathogens are involved in the etiology of this disease. The mechanistic insight of why pustule is developed only in PPP, but not in other sweatrelated diseases such as miliaria, remains unknown. Possibly, the thick horny layer of palms and soles is critically involved in the typical pustule formation of PPP. These issues remain to be clarified to dissect the pathomechanism of PPP in the future studies.
MATERIALS AND METHODS
PPP volunteers
The study was conducted according to the Declaration of Helsinki Principles. After obtaining approval from the ethics committee of Asahikawa Medical College, 15 volunteer patients (13 females and 2 males; mean age: 62.7±18.5 years; range 33-82) with a 2-to 10-year history of PPP were recruited for this study with informed consent. They had not been treated with any medications before. These patients were diagnosed by at least two board-certified dermatologists according to the clinical features. After obtaining informed consent, 15 samples for biopsy and 5 samples for blood and lesional vesicle/pustule samples were collected.
Dermatoscopy
The palms and soles of the patients were examined using a dermatoscope (Derma 9500C; KOS Medical K. K., Kanagawa, Japan). The pictures were recorded and stored as digital files. Dermatoscopy work was completed by a dermatologist and then checked by another board-certified dermatologist.
Sweat measurement
To see whether a sweat secretion problem existed on the lesional area of the skin, palmar sweat volume was measured using a cutaneous evaporation meter (portable sweat meter TS-100; TECHNO SCIENCE, Tokyo, Japan) according to the ventilation capsule method (Tomioka et al., 2005; Ohshima et al., 2008) , and was compared with nonlesional areas. Probe (1 cm 2 ) of the sweat meter was applied on the target skin area, and the 2-minute sweat volume was measured at both the lesional and nonlesional areas on the palms of the PPP patients. To see the increase in the paininduced sweating, the total 2-minute sweat volume after pin-prick stimulation was also measured in both lesional and nonlesional areas. The measurement was repeated three times on the same patient.
Tissue and vesicular fluid sampling
Excisional biopsies (approximately 10 mm in size) were taken from palmar lesions of 15 PPP cases with informed consent. The specimens were fixed in 10% buffered formalin overnight and were embedded in paraffin blocks for routine pathological diagnosis. The 4 mm sections were prepared for hematoxilin and eosin, as well as for immunostaining. Horizontal slices of 5 mm thickness were also prepared for additional immunostaining to distinguish the acrosyringium (vide infra).
Using a micropipetter, the fluid obtained from the vesicles or vesicopustules was collected from five patients immediately after cutting the top off the lesion and was placed into a 1.5 ml centrifuge tube. Several vesicles in the area of the lesion were collected and mixed together. In all, 1 ml of phosphate-buffered saline (PBS) was added and the sample was centrifuged at 15,000 r.p.m. for 5 minutes and spun down. The supernatant was then lyophilized with a Speed Vac (Savant Instruments, Inc, Farmingdale, NY) overnight, and the pellet was resuspended in 50 ml of double-distilled water for western blot and dot-blot analyses. All samples were then stored at À80 1C until use.
L-PMN collection from the lesion
For western blot and real-time PCR analyses, PMNs from palmar pustules (L-PMNs) were collected from five patients. The cells were obtained from the lesion with a micropipette after a small incision into the pustule. Collected L-PMNs were washed with PBS three times and then re-suspended in 100 ml of PBS. Using venipuncture, 4 ml of blood was drawn. B-PMNs were isolated and then processed with Polymorphprep (Axis-Shield PoC AS, Oslo, Norway) according to the manufacture's instruction. The samples were re-suspended in 100 ml of PBS. All samples were stored at À80 1C until use for RNA and protein extractions.
Antibodies
Rabbit polyclonal antibody to LL-37 used for immunostaining was developed against full-length LL-37 (Murakami et al., 2005) . Mouse monoclonal antibody to dermcidin (G-18; Santa Cruz Biotechnology, Santa Cruz, CA), mouse monoclonal antibody to EMA (clone E29; DAKO, Glostrup, Denmark), and mouse monoclonal antibody to GCDFP-15 (BRST-2, clone D6; Signet Laboratories, Dedham, MA) were purchased.
Synthetic peptides for LL-37 and dermcidin
Synthetic LL-37 was commercially prepared by Peptide Institute (Osaka, Japan), and synthetic dermcidin and its precursor Y-P30 (Schittek et al., 2001) , as a negative control, were prepared by Synpep (Dublin, CA). Peptide amino acid sequences were LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES for LL-37, SSLLEK GLDGAKKAVGGLGKLGKDAVEDLESVGKGAVHDVKDVLDSVL for dermcidin, and YDPEAASAPGSGNPCHEASAAQKENAGEDP for Y-P30. The synthetic peptides were purified to over 95% by HPLC and their identity was confirmed by mass spectrometry, respectively.
Western blot analysis
Protein extraction from PMN samples was performed by acidification with 1% trifluoroacetic acid and 1 M hydrochloric acid. In brief, 500 ml of 1% trifluoroacetic acid and 1 M hydrochloric acid solution was added to the PMN samples, vortexed well to destroy the cells, and then incubated at room temperature (RT) for 30 minutes. After centrifuging, the supernatant was collected, concentrated by lyophilization, and resuspended in 50 ml of double-distilled water. All samples were stored at À30 1C until use. Protein samples from PMNs and the vesicle/pustule fluids (10 ml) were separated by 16% Tricine gel (Invitrogen, Carlsbad, CA), respectively, and then transferred onto a polyvinylidene difluoride membrane (immobilone-P; Millipore, Bedford, MA). A total of 10 nmol of LL-37 (as a positive control) and dermcidin (as a negative control) synthetic peptides were also applied, respectively. The membrane was blocked with 5% nonfat milk in 0.1% TTBS (0.1% Tween-20/tris-buffered saline (TBS)) for 60 minutes at RT, and then rabbit anti-LL-37 polyclonal antibody (1:5,000 in the 5% nonfat milk in 0.1% TTBS) was applied on the membrane overnight 4 1C. After washing the membrane three times with 0.1% TTBS, horseradish peroxidase-labeled goat antirabbit IgG polyclonal antibody (1:5,000 in the blocking solution; Bio-Rad Laboratories, Hercules, CA) was incubated with the membrane for 60 minutes at RT. After washing the membrane with 0.1% TTBS, the membrane was immersed in enhanced chemiluminescence solution (Western Lightning Chemiluminescence Reagents Plus; New Lifescience Products, Boston, MA) for 60 seconds, and was then visualized with LAS-3000 imaging system (Fujifilm, Tokyo, Japan) according to the manufacture's instruction.
Dot-blot analysis
Dermcidin expression in the PPP fluid was evaluated by dot-blot analysis. In brief, 1 ml of fluid samples from the PPP patient was applied onto a nitrocellulose membrane with 32 nmol of dermcidin. The Y-P30 and LL-37 synthetic peptides were used as negative controls. After air-drying the membrane, the immunoreaction was visualized as described above with anti-dermcidin antibody in the blocking solution overnight at 4 1C. After washing the membrane with 0.1% TTBS, a horseradish peroxidase-labeled goat anti-mouse IgM polyclonal antibody (1:5,000 in the blocking solution; Santa Cruz Biotechnology) was applied as the second antibody for 60 minutes at RT. After washing with 0.1% TTBS, the membrane was immersed in enhanced chemiluminescence solution for 60 seconds and was then visualized with LAS-3000 imaging system.
Immunohistochemistry
Tissue sections were immersed in PBS after deparaffinization, and endogenous peroxidase activity was blocked by incubating with 0.3% H 2 O 2 in methanol for 30 minutes. After washing with PBS, the immunostaining with rabbit anti-LL-37 (1:100) and mouse antidermcidin (1:100) antibodies was performed using Histofine SAB-PO kits (Nichirei Biosciences, Tokyo, Japan) according to the manufacture's instruction. To visualize the sweat pore structure, horizontal slices were obtained and stained with mouse anti-EMA (1:100) and GCDFP-15 antibodies (1:100). As a negative control, the polyclonal antibody and monoclonal antibodies were replaced by normal rabbit and mouse preimmune IgG diluted with PBS containing 3% BSA at the same protein concentration used for the primary antibodies. All procedures were carried out at RT except for the first antibody incubation (4 1C, overnight).
Reverse transcription-PCR and real-time quantitative PCR
Total RNA was extracted from PMNs using RNeasy Mini kit (Qiagen, Valencia, CA), and complementary DNA was prepared from 1 mg of total RNA using iScript complementary DNA synthesis kit (Bio-Rad Laboratories) according to the manufacture's instruction. PCR amplification of LL-37 was performed with the forward primer (5 0 -GATAACAAGAGATTTGCCCTGCTG-3 0 ) and the reverse primer (5 0 -TTTCTCAGAGCCCAGAAGCCTG-3 0 ) for a 173-bp product. Amplification of 18S rRNA was carried out in parallel for all the samples with QuantumRNA classic 18S internal standard kit (Ambion, Woodward Austin, TX). PCR protocol was denaturation at 90 1C for 10 minutes, followed by 35 cycles of amplification with denaturation at 94 1C for 30 seconds, primer annealing at 50 1C for 30 seconds, and extension at 72 1C for 1 minute. After the reverse transcription-PCR, real-time quantitative PCR was performed using a LightCycler 2.0 system (Roche Diagnostics, Manheim, Germany) to compare the mRNA expression levels. RT reaction was performed in 2 ml of DNA Master SYBR Green I (Roche) and 2 ml of each 5 mM primer as described above. Amplification of GAPDH was carried out in parallel for all samples with LightCycler-primer set for Human GAPDH (Roche Diagnostics). Thermal profile was as follows: 95 1C for 10 seconds, 40 Â (94 1C for 15 seconds and 60 1C for 1 minute). Results were analyzed using the comparative Ct method, in which Ct indicates the number of cycles required to reach an arbitrary threshold (Dorschner et al., 2003) .
Statistical analysis
The data of the sweat measurement and the real-time PCR were evaluated using STATFLEX software (version 4.2; ARTEC, Osaka, Japan). Nonparametric t-test (Mann-Whitney U-test) was applied to compare differences between L-and B-PMNs. A Po0.05 was considered to be significant.
